Sara M Weis

US Patent:

20180203014, Jul 19, 2018

Filed:

Apr 20, 2016

Appl. No.:

15/568419

Inventors:

- Oakland CA, US
Laetitia SEGUIN - San Diego CA, US
Yu FUJITA - San Diego CA, US
Sara WEIS - San Diego CA, US

International Classification:

G01N 33/574
C12Q 1/6886
G01N 33/50

Abstract:

Provided are compositions, including kits, and methods comprising use of a biomarker βintegrin, including the αβintegrin, for detecting circulating tumor cells (CTCs), tumor stem cells, extracellular vesicles (EV), including exosomes and microvesicles, that are released by CTCs or cancer cells, as well as the tumor from which the CTCs or EVs derive, and to make a patient prognosis, and to assess tumor progression, and drug resistance (for example, resistance to tyrosine kinase inhibitors), e.g., for several cancers including: breast, colon, lung and pancreatic cancers. In alternative embodiments, a patient fluid sample, e.g., a blood, serum, urine, CSF or other sample, is taken and used to detect cancer stem cells, EVs- and/or CTCs-comprising βintegrin and/or a αβintegrin. Provided are compositions, including kits, and methods and uses of the biomarker βintegrin for anti-cancer drug design. In alternative embodiments, applications of compositions, including kits, and methods and uses as provided herein include conjugation of an imaging or therapeutic agent to an antibody targeting integrin βfor detection and/or targeted destruction of integrin βexpressing cancer stem cells and/or CTCs.